Skip to main content

Table 4 Random-effects pooled results: gabapentin vs. placebo.

From: Meta-analysis of duloxetine vs. pregabalin and gabapentin in the treatment of diabetic peripheral neuropathic pain

Outcome Treatment effect (θ) 95% CI for θ U-test
(p-value)
τ 2 NNT/NNH
(95% CI)
Efficacy      
Reduction in 24-hour pain intensity -1.437 (-2.211; -0.663) <0.001 0.109 *
Tolerability      
Premature study discontinuation due to:      
- Lack of efficacy -1.066 (-2.786; 0.653) 0.224 0  
- Adverse events 0.241 (-0.786; 1.267) 0.646 0 63 (30; ∞)
- Other -0.036 (-1.162; 1.090) 0.950 0  
Diarrhoea 0.393 (-0.555; 1.341) 0.416 0  
Dizziness 1.833 (0.834; 2.833) <0.001 0  
Headache 1.146 (-0.018; 2.310) 0.054 0  
Nausea 0.595 (-0.532; 1.722) 0.301 0  
Somnolence 1.582 (0.643; 2.520) 0.001 0  
  1. Note:
  2. θ is absolute difference for 24-hour pain intensity.
  3. θ is log-odds ratio for all tolerability analyses.
  4. τ 2 is between-study heterogeneity.
  5. NNT/NNH: Number needed to treat, number needed to harm. * NNT was not calculated, due to absence of required binary data on responder rates. NNH was calculated for discontinuation due to adverse events.